Jim Glasheen

General Partner
Technology Partners

Jim is a General Partner at Technology Partners and has been with the firm since early 2002, leading the efforts in Consumer Medicine. He serves on the boards of ElCelyx, Essentialis, Incline Therapeutics, Medley Health, Revance Therapeutics and TRIA Beauty, while also having led Technology Partner's investment in two companies that have since gone public- Iomai (IOMI) and Cadence Pharmaceuticals (CADX). Jim is also an advisor to the Lester Center at UC Berkeley and the National Science Foundation (NSF) in Washington, DC. Previously, Jim was Managing Director at CIT Venture Capital, leading the Group's efforts in Life Science investing. Also, Jim was a leader within McKinsey & Company's Pharmaceutical & Medical Products Practice. Jim earned a B.S. from Duke University and a M.A./Ph.D. from Harvard University in Biology. He was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany, and a post-doctoral fellow at UC Berkeley. Jim has published several papers and has had his research highlighted in major media outlets, including: Nature, The New York Times, Scientific American and CNN.